Commentary|Videos|August 18, 2025

The Reality of Operational Flexibility for Trial Sites

In this video interview, Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), discusses the challenges of achieving true operational flexibility in clinical trials—highlighting how SOPs, staffing, and budget constraints often limit site adaptability and contribute to staff burnout.

In a recent video interview Applied Clinical Trials, Caroline Potts, general manager of sites and patient services, Medical Research Network (MRN), discussed operational flexibility in clinical trials, emphasizing the need to avoid staff burnout due to inflexible SOPs and budget constraints. She highlighted strategies such as in-home visits and community outreach as essential for reducing recruitment delays and improving trial diversity. Potts also touched on budgetary issues as a major barrier to patient-centric models, with a call for better dialogue and innovative solutions. She stressed the importance of community engagement, temporary clinic sites, and collaborative efforts among key stakeholders to better serve diverse populations in clinical trials.

ACT: What does operational flexibility really look like for sites today? How can it be implemented without adding to staff burnout?

Potts: I think the key point there is the staff burnout. I think everyone likes to genuinely believe that operational flexibility exists, and I'm just not sure that that is the true lived experience of site staff. I think that everyone wants to do a good job, everyone wants to be able to offer solutions that perhaps are nonstandard, or seen as nonstandard, but SOPs, budgetary constraints, time constraints, availability of staff, availability of patients, all of those things can—more often than not—count against this idea of having the flexibility. I think that it does run the risk of leading to staff burnout as a result of that, unfortunately. It's a great concept, and I think everyone should still continue to try to strive for it, but I think the reality is a little bit different to that.


Related to this article

The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
Better Site Training Starts With Five Simple Questions
Site training effectiveness depends on readiness at first-patient-in, requiring learning-science design principles around performance focus, cognitive load reduction, progressive sequencing, and spaced retrieval practice rather than training completion metrics or content volume.